ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

Effective July1, 2017, Adaptimmune Therapeutics plc (the “Company” or “Adaptimmune”), assigned to Immunocore Limited (“Immunocore”) all of the Company’s rights, interests, obligations and responsibilities under a lease, dated as of June24, 2015, between MEPC Milton Park No.1 Limited and MEPC Milton Park No.2 Limited (the “Landlord”) and the Company with respect to approximately 9,695 square feet of office space at Building 101, Milton Park, Oxfordshire, U.K. (the “Lease Assignment”). The Landlord consented to the Lease Assignment on June30, 2017.

The Lease Assignment followed the relocation of the Company’s staff into the Company’s new 67,140 square foot building at Milton Park, Oxfordshire (“Building 60”) in June2017. Building 60 comprises laboratory and office space and accommodates all of the Company’s U.K. operations.


About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

An ad to help with our costs